Weil-Olivier, Catherine http://orcid.org/0000-0001-5271-1945
Taha, Muhamed-Kheir http://orcid.org/0000-0002-0716-3174
Leng, Sean http://orcid.org/0000-0002-2690-8055
Dinleyici, Ener Cagri http://orcid.org/0000-0002-0339-0134
Bonanni, Paolo http://orcid.org/0000-0003-2875-3744
Moya, Elena
Leischker, Andreas http://orcid.org/0000-0001-6390-2640
Yezli, Saber http://orcid.org/0000-0002-3380-7092
Funding for this research was provided by:
Sanofi
Article History
Received: 18 December 2023
Accepted: 27 February 2024
First Online: 6 May 2024
Declarations
:
: MKT conducts work contracts funded by GSK, Pfizer and Sanofi for the Institut Pasteur, Paris. He also reports the patent NZ630133A “Vaccines for serogroup X meningococcus” issued with GSK. SL declares participation in Sanofi’s International Advisory Board on SARS-CoV-2 vaccine development and engaged in speaking for GSK on Shingrix vaccine. ECD declares performing contract work for Eskisehir Osmangazi University, funded by GSK, Sanofi Pasteur, and Pfizer. PB declares speaking engagements and participation in Advisory Boards for GSK, MSD, Pfizer, Seqirus, Astra Zeneca, Janssen, Sanofi Pasteur, and Moderna. AL declares consulting fees and participation in Advisory Boards for Sanofi Pasteur, and being a member of the “Working Group on Vaccination” of the German Geriatric Society. SY declares receiving consultation fees, travel grants, and honoraria from Sanofi for attending scientific meetings and presentations. CWO declares participation to speaking engagements and in Advisory boards for Sanofi, Pfizer, Sequirus, Astra-Zeneca, Janssen and Novavax; and EM declare no competing interests.
: For this review, no informed consent is required.
: For this review, no ethical approval is required.